中国临床药理学杂志Issue(8)：612-614,3.DOI:10.13699/j.cnki.1001-6821.2015.08.009
吉西他滨联合奥沙利铂或卡培他滨治疗晚期胰腺癌的临床疗效及安全性评价
Gemcitabine combined with oxaliplatin or capecitabine in the treatment of advanced pancreatic cancer
摘要
Abstract
Objective To investigate the clinical efficacy and safety of gemcitabine combined with oxaliplatin or capecitabine on advanced pan-creatic cancer.Methods A total of sixty-six cases of advanced pan-creatic cancer from the first people ’ s hospital of huzhou and first affilia-ted hospital of fujian medical university were recruited in this study from February 2012 to August 2014.The included 66 patients were rando-mized divided into the control group ( n=32 ) and test group ( n=34 ) . Patients in the control group received gemcitabine 1000 mg・ m-2 through intravenous drip in 30 min on day 1 and 8 combined with oxaliplatin 135 mg・ m-2 through intravenous drip in 2 h on day 1.Patients in the test group received gemcitabine 1000 mg・ m-2 through intravenous drip in 30 min on day 1 and 8 combined with capecitabine 1250 mg・ m-2 orally , bid between day 1 to day 14 , with twenty one days as a cycle .The treat-ment lasted for four cycles in two groups .The data of clinical efficacy and adverse reactions were measured in the two groups .Results The data of objective response rate (ORR), half year survival and 1-year survival rate were 55.9%, 76.5%, 26.5% in the test group and 40.6%, 71.9% and 18.8% in control group.The ORR in test group was significantly higher than in the control group (P<0.05).The grade Ⅲ-Ⅳnauseaandvomiting,myelosuppressionwerenotsignificantlydifferentintwogroups(P>0.05).Conclusion Gemcitabine combined with capecitabine in the treatment of advanced pancreatic cancer is effective with less chemo -therapy related adverse reactions .关键词
晚期胰腺癌/吉西他滨/奥沙利铂/卡培他滨/临床疗效/不良反应Key words
advanced pancreatic cancer/gemcitabine/oxaliplatin/capecitabine/efficacy/adverse drug reaction分类
医药卫生引用本文复制引用
李小明,胡爱虹,张帆..吉西他滨联合奥沙利铂或卡培他滨治疗晚期胰腺癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,(8):612-614,3.基金项目
福建省自然科学基金资助项目 （）
